SLC1A2 and central nervous system cancer: We observed that DEX treatment decreases the expression of GLT-1 mRNA and protein in C6 glioma cells in vitro, consistent with our finding in vivo showing the reduction in GLT-1 expression in the frontal cortex by neonatal DEX treatment.